Published in J Mol Model on May 12, 2011
Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol (1999) 3.63
Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos (2004) 3.00
Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature (2003) 2.99
Crystal structure of human cytochrome P450 2D6. J Biol Chem (2005) 2.34
The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem (2004) 2.24
Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev (1997) 2.16
MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem (2005) 1.61
Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos (2000) 1.40
Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol (2003) 1.35
Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol (2007) 1.27
Theoretical characterization of substrate access/exit channels in the human cytochrome P450 3A4 enzyme: involvement of phenylalanine residues in the gating mechanism. J Phys Chem B (2009) 1.23
Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos (1996) 1.21
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos (2004) 1.20
Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol (2000) 1.14
The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica (1986) 1.14
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol (2007) 1.09
Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Mol Pharmacol (2004) 1.08
Prediction of cytochrome P450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines. J Chem Inf Model (2005) 1.07
Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol (2001) 1.04
Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol (1996) 1.03
Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem (2002) 1.00
Reaction site mapping of xenobiotic biotransformations. J Chem Inf Model (2007) 1.00
Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res (1985) 1.00
Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology (1999) 1.00
Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology (1997) 0.99
Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther (2000) 0.97
(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos (2000) 0.94
CypScore: Quantitative prediction of reactivity toward cytochromes P450 based on semiempirical molecular orbital theory. ChemMedChem (2009) 0.91
A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol (1992) 0.91
Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug Metab Dispos (2004) 0.90
Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates. J Chem Inf Model (2007) 0.90
In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet (2003) 0.89
Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. Biochem Biophys Res Commun (2000) 0.89
Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity. Drug Metab Dispos (2000) 0.88
Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metab Dispos (1996) 0.87
Synergistic use of compound properties and docking scores in neural network modeling of CYP2D6 binding: predicting affinity and conformational sampling. J Chem Inf Model (2006) 0.86
Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6. Proteins (2002) 0.85
Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J Med Chem (2002) 0.85
Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther (1999) 0.85
Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity. J Biol Chem (2001) 0.82
The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. Biochemistry (1995) 0.82
Minimum requirements of hydrophobic and hydrophilic features in cationic peptide antibiotics (CPAs): pharmacophore generation and validation with cationic steroid antibiotics (CSAs). J Mol Model (2008) 0.81
Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos (1999) 0.81
Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res (2005) 0.81
Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol (2004) 0.81
Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity. Drug Metab Dispos (2000) 0.80
Shape- and chemical feature-based 3D-pharmacophore model generation and virtual screening: identification of potential leads for P. falciparum DHFR enzyme inhibition. Chem Biol Drug Des (2009) 0.80
Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation. Drug Metab Dispos (2004) 0.80
Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica (2004) 0.80
Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica (1996) 0.80
Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem Pharmacol (1996) 0.79
In vitro prediction and in vivo verification of enantioselective human tofisopam metabolite profiles. Drug Metab Dispos (2007) 0.76
Evaluation of descriptors and classification schemes to predict cytochrome substrates in terms of chemical information. J Comput Aided Mol Des (2008) 0.76
N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase. J Med Chem (2011) 1.07
Bonding trends of thiosemicarbazones in mononuclear and dinuclear copper(I) complexes: syntheses, structures, and theoretical aspects. Inorg Chem (2006) 0.98
Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur J Pharm Sci (2004) 0.98
Conformational polymorphism in sulfonylurea drugs: electronic structure analysis. J Phys Chem B (2010) 0.97
A study of BF3-promoted ortho lithiation of anilines and DFT calculations on the role of fluorine-lithium interactions. Angew Chem Int Ed Engl (2008) 0.90
Structure-based approaches in the design of GSK-3 selective inhibitors. Curr Protein Pept Sci (2007) 0.87
Modelling and informatics in the analysis of P. falciparum DHFR enzyme inhibitors. Curr Med Chem (2008) 0.85
Carbene generation by cytochromes and electronic structure of heme-iron-porphyrin-carbene complex: a quantum chemical study. Inorg Chem (2013) 0.85
3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors. J Mol Graph Model (2006) 0.84
Computer-aided molecular design of 1H-imidazole-2,4-diamine derivatives as potential inhibitors of Plasmodium falciparum DHFR enzyme. J Mol Model (2010) 0.84
Dendrimer building toolkit: model building and characterization of various dendrimer architectures. J Comput Chem (2012) 0.84
Minimum requirements of hydrophobic and hydrophilic features in cationic peptide antibiotics (CPAs): pharmacophore generation and validation with cationic steroid antibiotics (CSAs). J Mol Model (2008) 0.81
A common feature-based 3D-pharmacophore model generation and virtual screening: identification of potential PfDHFR inhibitors. J Enzyme Inhib Med Chem (2010) 0.81
Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics. Cancer Chemother Pharmacol (2009) 0.80
Shape- and chemical feature-based 3D-pharmacophore model generation and virtual screening: identification of potential leads for P. falciparum DHFR enzyme inhibition. Chem Biol Drug Des (2009) 0.80
3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity. Eur J Med Chem (2007) 0.79
Site-selective electrophilic cyclization and subsequent ring-opening: a synthetic route to pyrrolo[1,2-a]quinolines and indolizines. J Org Chem (2012) 0.79
5-Fluorouracil mediated anti-cancer activity in colon cancer cells is through the induction of Adenomatous Polyposis Coli: Implication of the long-patch base excision repair pathway. DNA Repair (Amst) (2014) 0.79
Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening. Chem Biol Drug Des (2006) 0.79
Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening. Eur J Med Chem (2009) 0.79
Origin of 1,3-induction in the addition of alkyl lithium to imines bearing an N-stereogenic center. Chem Commun (Camb) (2003) 0.78
Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma. J Med Chem (2005) 0.78
Divalent N(I) character in 2-(thiazol-2-yl)guanidine: an electronic structure analysis. J Phys Chem A (2012) 0.78
3D-QSAR studies of substituted 1-(3, 3-diphenylpropyl)-piperidinyl amides and ureas as CCR5 receptor antagonists. J Mol Model (2007) 0.78
2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. Eur J Med Chem (2012) 0.78
Electronic structure and reactivity of guanylthiourea: a quantum chemical study. J Comput Chem (2010) 0.78
To bend or not to bend! The dilemma of allenes. J Org Chem (2011) 0.77
New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies. Bioorg Med Chem Lett (2008) 0.77
Novel (+)N(<--L)2 species with two lone pairs on nitrogen: systems isoelectronic to carbodicarbenes. Chem Commun (Camb) (2009) 0.77
C-H bond functionalization under metalation-deprotonation process: regioselective direct arylation of 3-aminoimidazo[1,2-a]pyrazine. J Org Chem (2012) 0.77
Metabolic-intermediate complex formation with cytochrome P450: theoretical studies in elucidating the reaction pathway for the generation of reactive nitroso intermediate. J Comput Chem (2012) 0.77
New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies. Bioorg Med Chem Lett (2008) 0.77
In(III) triflate-mediated solvent-free synthesis and activation of thioglycosides by ball milling and structural analysis of long chain alkyl thioglycosides by TEM and quantum chemical methods. J Org Chem (2014) 0.77
Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening. Biophys Chem (2007) 0.77
New leads for selective GSK-3 inhibition: pharmacophore mapping and virtual screening studies. J Comput Aided Mol Des (2006) 0.77
A new chiral shift reagent for the determination of enantiomeric excess and absolute configuration in cyanohydrins. Chem Commun (Camb) (2009) 0.77
Mechanism-based inactivation of cytochromes by furan epoxide: unraveling the molecular mechanism. Inorg Chem (2013) 0.77
Structural elaboration of a natural product: identification of 3,3'-diindolylmethane aminophosphonate and urea derivatives as potent anticancer agents. ChemMedChem (2013) 0.77
'Sum of activities' as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists. Eur J Med Chem (2008) 0.77
Divalent N(I) compounds with two lone pairs on nitrogen. J Phys Chem A (2011) 0.77
Origins of the specificity of inhibitor P218 toward wild-type and mutant PfDHFR: a molecular dynamics analysis. J Biomol Struct Dyn (2014) 0.76
3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme. J Mol Graph Model (2009) 0.76
CoMFA analysis of dual/multiple PPAR activators. Eur J Med Chem (2008) 0.76
Comparative molecular similarity indices analysis (CoMSIA) studies of 1,2-naphthoquinone derivatives as PTP1B inhibitors. Bioorg Med Chem (2005) 0.76
Design of glycogen synthase kinase-3 inhibitors: an overview on recent advancements. Curr Pharm Des (2013) 0.76
Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy. Anticancer Drugs (2014) 0.76
Pharmacoinformatic approaches to understand complexation of dendrimeric nanoparticles with drugs. Nanoscale (2014) 0.75
Structure based de novo design of novel glycogen synthase kinase 3 inhibitors. Bioorg Med Chem (2007) 0.75
Comparative 3D QSAR study on β(1)-, β(2)-, and β(3)-adrenoceptor agonists. Med Chem Res (2009) 0.75
Pharmacophoric features of drugs with guanylurea moiety: an electronic structure analysis. J Mol Model (2013) 0.75
Formation/fate of reactive metabolites from general anesthetics and a comparison of toxic and non-toxic analogues: a DFT study. Drug Metab Lett (2012) 0.75
Toxic metabolite formation from Troglitazone (TGZ): new insights from a DFT study. Chem Res Toxicol (2011) 0.75
CuBr catalyzed aerobic oxidative coupling of 2-aminopyridines with cinnamaldehydes: direct access to 3-formyl-2-phenyl-imidazo[1,2-a]pyridines. Org Biomol Chem (2015) 0.75
Synthesis of 2-phenylnaphthalenes from styryl-2-methoxybenzenes. Chem Commun (Camb) (2014) 0.75
An experimental and computational study of stereoselectivity and reactivity in Lewis acid promoted lithiation-substitution of tertiary amines. J Am Chem Soc (2007) 0.75
Cu-catalyzed arylation of the amino group in the indazole ring: regioselective synthesis of pyrazolo-carbazoles. Org Biomol Chem (2015) 0.75
A simple, mild, and regioselective method for the benzylation of carbohydrate derivatives promoted by silver carbonate. Carbohydr Res (2010) 0.75
Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies. Eur J Med Chem (2007) 0.75
Design of benzene-1,2-diamines as selective inducible nitric oxide synthase inhibitors: a combined de novo design and docking analysis. J Mol Model (2008) 0.75
Possibility of the existence of donor-acceptor interactions in bis(azole)amines: an electronic structure analysis. J Org Chem (2014) 0.75
A new colorimetric chemodosimeter for Hg2+ based on charge-transfer compound of N-methylpyrrole with TCNQ. Talanta (2010) 0.75
S-oxidation of thiazolidinedione with hydrogen peroxide, peroxynitrous acid, and C4a-hydroperoxyflavin: a theoretical study. J Phys Chem A (2011) 0.75
Cobalt(II) catalyzed C(sp)-H bond functionalization of alkynes with phenyl hydrazines: facile access to diaryl 1,2-diketones. Org Biomol Chem (2015) 0.75
Investigation of anion-π interactions involving thiophene walls incorporated calix[4]pyrroles. J Org Chem (2015) 0.75
Studies on some glitazones having pyridine as the linker unit. Bioorg Med Chem (2004) 0.75
Synthesis, in vitro and in silico evaluation of l-tyrosine containing PPARalpha/gamma dual agonists. Bioorg Med Chem (2006) 0.75
Density functional study on the cytochrome-mediated S-oxidation: identification of crucial reactive intermediate on the metabolic path of thiazolidinediones. J Phys Chem A (2012) 0.75
Entrapment and kinetic resolution of stabilized axial and equatorial conformers of spiro-β-lactams. J Org Chem (2011) 0.75
3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3β inhibitors. Chem Biol Drug Des (2012) 0.75
Chiral solvating agents for cyanohydrins and carboxylic acids. J Org Chem (2010) 0.75
Importance of cytochromes in cyclization reactions: quantum chemical study on a model reaction of proguanil to cycloguanil. J Comput Chem (2014) 0.75
On the stability of zwitterions of pyridine sulfonylureas: the effect of isosterism, acidity, and microsolvation. J Phys Chem A (2013) 0.75
3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors. Med Chem (2007) 0.75
3D-QSAR studies of pyruvate dehydrogenase kinase inhibitors based on a divide and conquer strategy. Bioorg Med Chem (2004) 0.75
Self-association behavior of a novel nonproteinogenic β-strand-mimic in an organic solvent. J Phys Chem B (2014) 0.75
Existence of dynamic tautomerism and divalent N(I) character in N-(pyridin-2-yl)thiazol-2-amine. J Comput Chem (2013) 0.75